Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cisplatin 10pembrolizumab 8Carboplatin 8Paclitaxel 6durvalumab 5Pemetrexed 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5osimertinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Taxes 3Nivolumab 3Gemcitabine 3Docetaxel 3Bevacizumab 3cabozantinib 2atezolizumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Platinum 2Immunoglobulin G 2Disulfides 2CP protocol 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2trifluridine tipiracil drug combination 1tremelimumab 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma × PE regimen × Clear all
NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

AstraZeneca

Phase 3 Active not recruiting
328 enrolled 23 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡